Loading...

Genmab

CPSE:GEN
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
GEN
CPSE
DKK73B
Market Cap
  1. Home
  2. DK
  3. Pharmaceuticals & Biotech
Company description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The last earnings update was 39 days ago. More info.


Add to Portfolio Compare Print
GEN Share Price and Events
7 Day Returns
0.3%
CPSE:GEN
0.5%
DK Biotechs
1.6%
DK Market
1 Year Returns
22.8%
CPSE:GEN
18.7%
DK Biotechs
1.8%
DK Market
GEN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Genmab (GEN) 0.3% 2.5% 5.6% 22.8% 7.5% 405.1%
DK Biotechs 0.5% 3% 6.7% 18.7% 5.3% 288.7%
DK Market 1.6% 2.2% 0.2% 1.8% 17.4% 35.1%
1 Year Return vs Industry and Market
  • GEN outperformed the Biotechs industry which returned 18.7% over the past year.
  • GEN outperformed the Market in Denmark which returned 1.8% over the past year.
Price Volatility
GEN
Industry
5yr Volatility vs Market

Value

 Is Genmab undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of Genmab to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for Genmab.

CPSE:GEN Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 17 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 7.5%
Perpetual Growth Rate 10-Year DK Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for CPSE:GEN
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DK Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.32
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.318 (1 + (1- 22%) (0.27%))
1.215
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.22
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.21% + (1.215 * 5.96%)
7.46%

Discounted Cash Flow Calculation for CPSE:GEN using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for Genmab is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

CPSE:GEN DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (DKK, Millions) Source Present Value
Discounted (@ 7.46%)
2019 1,697.50 Analyst x6 1,579.73
2020 2,156.17 Analyst x6 1,867.36
2021 2,458.50 Analyst x4 1,981.48
2022 2,685.72 Est @ 9.24% 2,014.44
2023 2,861.20 Est @ 6.53% 1,997.17
2024 2,993.88 Est @ 4.64% 1,944.80
2025 3,092.99 Est @ 3.31% 1,869.78
2026 3,166.64 Est @ 2.38% 1,781.50
2027 3,221.45 Est @ 1.73% 1,686.59
2028 3,262.54 Est @ 1.28% 1,589.60
Present value of next 10 years cash flows DKK18,312.46
CPSE:GEN DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= DKK3,262.54 × (1 + 0.21%) ÷ (7.46% – 0.21%)
DKK45,148.09
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= DKK45,148.09 ÷ (1 + 7.46%)10
DKK21,997.46
CPSE:GEN Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= DKK18,312.46 + DKK21,997.46
DKK40,309.92
Equity Value per Share
(DKK)
= Total value / Shares Outstanding
= DKK40,309.92 / 61.68
DKK653.53
CPSE:GEN Discount to Share Price
Calculation Result
Value per share (DKK) From above. DKK653.53
Current discount Discount to share price of DKK1,179.00
= -1 x (DKK1,179.00 - DKK653.53) / DKK653.53
-80.4%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of Genmab is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Genmab's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Genmab's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
CPSE:GEN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in DKK DKK21.96
CPSE:GEN Share Price ** CPSE (2019-06-14) in DKK DKK1179
Europe Biotechs Industry PE Ratio Median Figure of 29 Publicly-Listed Biotechs Companies 21.23x
Denmark Market PE Ratio Median Figure of 103 Publicly-Listed Companies 16.09x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Genmab.

CPSE:GEN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= CPSE:GEN Share Price ÷ EPS (both in DKK)

= 1179 ÷ 21.96

53.7x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genmab is overvalued based on earnings compared to the Europe Biotechs industry average.
  • Genmab is overvalued based on earnings compared to the Denmark market.
Price based on expected Growth
Does Genmab's expected growth come at a high price?
Raw Data
CPSE:GEN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 53.7x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts
22.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 23 Publicly-Listed Biotechs Companies 1.23x
Denmark Market PEG Ratio Median Figure of 44 Publicly-Listed Companies 2.16x

*Line of best fit is calculated by linear regression .

CPSE:GEN PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 53.7x ÷ 22.6%

2.38x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genmab is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on Genmab's assets?
Raw Data
CPSE:GEN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in DKK DKK132.10
CPSE:GEN Share Price * CPSE (2019-06-14) in DKK DKK1179
Denmark Biotechs Industry PB Ratio Median Figure of 6 Publicly-Listed Biotechs Companies 3.46x
Denmark Market PB Ratio Median Figure of 136 Publicly-Listed Companies 1.61x
CPSE:GEN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= CPSE:GEN Share Price ÷ Book Value per Share (both in DKK)

= 1179 ÷ 132.10

8.93x

* Primary Listing of Genmab.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Genmab is overvalued based on assets compared to the DK Biotechs industry average.
X
Value checks
We assess Genmab's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. Genmab has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Genmab expected to perform in the next 1 to 3 years based on estimates from 17 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
22.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Genmab expected to grow at an attractive rate?
  • Genmab's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • Genmab's earnings growth is expected to exceed the Denmark market average.
  • Genmab's revenue growth is expected to exceed the Denmark market average.
Annual Growth Rates Comparison
Raw Data
CPSE:GEN Future Growth Rates Data Sources
Data Point Source Value (per year)
CPSE:GEN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 17 Analysts 22.6%
CPSE:GEN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 17 Analysts 18.6%
Denmark Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 22.5%
Europe Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 14.3%
Denmark Market Earnings Growth Rate Market Cap Weighted Average 10.4%
Denmark Market Revenue Growth Rate Market Cap Weighted Average 6.4%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
CPSE:GEN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
All numbers in DKK Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
CPSE:GEN Future Estimates Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 9,156 5,164 4,564 3
2022-12-31 7,792 4,233 3,903 4
2021-12-31 6,756 2,910 2,658 13
2020-12-31 5,556 2,366 2,098 17
2019-12-31 4,573 1,748 1,848 16
CPSE:GEN Past Financials Data
Date (Data in DKK Millions) Revenue Cash Flow Net Income *
2019-03-31 2,935 1,198 1,346
2018-12-31 3,025 1,015 1,472
2018-09-30 2,807 1,062 1,424
2018-06-30 2,532 892 1,239
2018-03-31 2,796 1,301 1,286
2017-12-31 2,365 1,589 1,104
2017-09-30 2,275 1,260 1,159
2017-06-30 2,316 1,422 1,354
2017-03-31 1,897 1,088 1,215
2016-12-31 1,816 328 1,187
2016-09-30 1,463 658 735
2016-06-30 1,376 591 686

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Genmab's earnings are expected to grow significantly at over 20% yearly.
  • Genmab's revenue is expected to grow by 18.6% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
CPSE:GEN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below

All data from Genmab Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:GEN Future Estimates Data
Date (Data in DKK Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31 71.16 78.61 63.70 2.00
2022-12-31 61.38 68.76 54.00 2.00
2021-12-31 40.06 53.70 10.98 10.00
2020-12-31 33.84 47.57 18.67 13.00
2019-12-31 28.64 32.34 16.99 11.00
CPSE:GEN Past Financials Data
Date (Data in DKK Millions) EPS *
2019-03-31 21.96
2018-12-31 24.03
2018-09-30 23.28
2018-06-30 20.29
2018-03-31 21.01
2017-12-31 18.14
2017-09-30 19.13
2017-06-30 22.41
2017-03-31 20.37
2016-12-31 19.83
2016-09-30 12.42
2016-06-30 11.56

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Genmab is expected to efficiently use shareholders’ funds in the future (Return on Equity greater than 20%).
X
Future performance checks
We assess Genmab's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Denmark market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Genmab has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Genmab performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Genmab's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Genmab has delivered over 20% year on year earnings growth in the past 5 years.
  • Genmab's 1-year earnings growth is less than its 5-year average (4.6% vs 33.6%)
  • Genmab's earnings growth has not exceeded the Europe Biotechs industry average in the past year (4.6% vs 16%).
Earnings and Revenue History
Genmab's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Genmab Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

CPSE:GEN Past Revenue, Cash Flow and Net Income Data
Date (Data in DKK Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 2,935.13 1,345.78 240.13 1,664.69
2018-12-31 3,025.14 1,472.14 213.70 1,431.16
2018-09-30 2,807.15 1,424.14 194.94 1,227.33
2018-06-30 2,532.00 1,239.29 177.14 1,111.86
2018-03-31 2,795.67 1,286.03 156.77 994.54
2017-12-31 2,365.44 1,103.55 146.99 852.06
2017-09-30 2,275.03 1,159.10 131.31 795.06
2017-06-30 2,316.25 1,353.73 121.16 717.89
2017-03-31 1,896.73 1,214.70 110.33 703.83
2016-12-31 1,816.12 1,187.08 102.41 660.88
2016-09-30 1,463.32 735.13 100.98 642.04
2016-06-30 1,376.42 686.44 94.35 605.93
2016-03-31 1,196.43 534.70 93.42 529.24
2015-12-31 1,133.04 763.51 91.22 487.66
2015-09-30 774.19 443.07 91.55 442.61
2015-06-30 767.94 462.72 90.47 440.80
2015-03-31 710.09 420.09 85.74 458.80
2014-12-31 850.39 301.30 79.53 505.68
2014-09-30 850.63 292.14 76.75 516.59
2014-06-30 728.77 137.56 71.81 534.30
2014-03-31 750.87 138.37 69.49 544.88
2013-12-31 663.57 70.16 66.74 527.58
2013-09-30 610.63 -4.69 64.06 538.53
2013-06-30 576.85 -54.68 65.41 535.35
2013-03-31 550.40 -21.39 65.07 528.75
2012-12-31 484.64 -111.45 64.61 536.70
2012-09-30 414.60 -130.91 62.47 525.26
2012-06-30 389.59 -94.91 64.04 529.34

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • Genmab has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • Genmab used its assets more efficiently than the Europe Biotechs industry average last year based on Return on Assets.
  • Genmab's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess Genmab's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Genmab has a total score of 2/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Genmab's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Genmab's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Genmab is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Genmab's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Genmab's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Genmab has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Genmab Company Filings, last reported 2 months ago.

CPSE:GEN Past Debt and Equity Data
Date (Data in DKK Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 8,127.16 199.43 6,830.27
2018-12-31 8,014.36 0.00 6,106.09
2018-09-30 7,079.17 0.00 5,895.42
2018-06-30 6,861.23 0.00 6,070.94
2018-03-31 6,520.10 0.00 5,701.17
2017-12-31 6,272.19 0.00 5,422.74
2017-09-30 5,466.85 0.00 5,183.90
2017-06-30 5,439.35 0.00 5,214.76
2017-03-31 5,006.22 0.00 4,750.63
2016-12-31 4,826.70 0.00 3,921.97
2016-09-30 3,934.11 0.00 3,942.47
2016-06-30 3,748.62 0.00 3,762.12
2016-03-31 3,521.25 0.06 3,490.52
2015-12-31 3,486.72 0.12 3,493.23
2015-09-30 3,039.18 0.18 3,205.61
2015-06-30 2,769.62 0.24 2,957.78
2015-03-31 2,588.15 0.30 2,945.13
2014-12-31 2,032.94 0.36 2,660.52
2014-09-30 1,933.56 0.42 2,638.51
2014-06-30 1,750.41 0.47 2,584.18
2014-03-31 1,764.11 0.54 2,529.77
2013-12-31 659.52 2.49 1,556.98
2013-09-30 513.35 156.71 1,651.26
2013-06-30 496.10 4.51 1,546.71
2013-03-31 488.16 4.73 1,489.37
2012-12-31 383.19 5.66 1,503.75
2012-09-30 368.35 7.39 1,178.61
2012-06-30 414.88 8.71 944.17
  • Genmab has no debt.
  • Genmab had no debt 5 years ago.
  • Genmab has no debt, it does not need to be covered by operating cash flow.
  • Genmab has no debt, therefore coverage of interest payments is not a concern.
X
Financial health checks
We assess Genmab's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Genmab has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Genmab's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Genmab dividends. Estimated to be 0.07% next year.
If you bought DKK2,000 of Genmab shares you are expected to receive DKK0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Genmab's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Genmab's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
CPSE:GEN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 17 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.8%
Denmark Market Average Dividend Yield Market Cap Weighted Average of 78 Stocks 2.4%
Denmark Minimum Threshold Dividend Yield 10th Percentile 1%
Denmark Bottom 25% Dividend Yield 25th Percentile 1.6%
Denmark Top 25% Dividend Yield 75th Percentile 4.8%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

CPSE:GEN Future Dividends Estimate Data
Date (Data in DKK) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 1.33 3.00
2020-12-31 0.75 4.00
2019-12-31 0.50 4.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Genmab has not reported any payouts.
  • Unable to verify if Genmab's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Genmab's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Genmab has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of Genmab's dividends in 3 years as they are not expected to pay a notable one for Denmark.
X
Income/ dividend checks
We assess Genmab's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Genmab afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Genmab has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Genmab's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Jan G. van de Winkel
COMPENSATION DKK28,287,000
AGE 57
TENURE AS CEO 9 years
CEO Bio

Dr. Jan G. J. van de Winkel, Ph.D., serves as a Member of Advisory board at Thuja Capital Management B.V. He served as a Member of Scientific Advisory Board. He is a Co-Founder of Genmab A/S. Dr. van de Winkel has been the Chief Executive Officer and President at Genmab A/S since June 15, 2010 and 2010 respectively. He served as the President of Research and Development at Genmab A/S. and served as its Chief Scientific Officer from June 1998 to 2010. He serves as an Advisor at AGLAIA BioMedical Ventures B.V. He is a Scientific Advisor to international venture capital firms. He has several years of experience in the therapeutic antibody field. He served as a Vice President and Scientific Director at Medarex Europe until 2000. In 1997, he set up a research unit for Genmab A/S. He holds a Professorship in Immunology at Utrecht University, The Netherlands. Dr. van de Winkel’s research focuses on the biological role and clinical application of antibodies. Within his laboratory clinical implications of Fc receptor heterogeneity and novel therapeutic strategies for cancer, autoimmune disorders and infectious diseases are studied. From 1992 to 1996, he was an Associate Professor at Utrecht University's Department of Experimental Immunology. From 1988 to 1992, he was a Post-Doctoral fellow at the Department of Experimental Immunology at Utrecht University, visiting Scientist at the Department of Internal Medicine of the Ohio State University and Assistant Professor at the Department of Experimental Immunology at Utrecht University. He serves as a Member of Life Sciences Advisory Board of Advent Venture Partners. He served as a Director of Forward Pharma A/S since August 12, 2014 until May 3, 2017. He serves as the Chairman of the Board of Directors of Regenesance and Member of the Board of Directors of ISA Pharmaceuticals and Celdara Medical and the Advisory Board of Capricorn Health-tech Fund. He is a Board Member of several biotech companies. Previously, he was a Member of Scientific Advisory Board of Biotechnology Turnaround Fund B.V. He has been responsible for a number of patents and pending patent applications and is the author of over 300 scientific publications. He is one of the leading scientists in the study of antibodies and their interaction with the human immune system. Dr. van de Winkel is widely recognized, as one of the leading scientists in the study of antibodies and their interaction with the immune system and has been responsible for a number of patents and patent applications. His research is supported by grants from Utrecht University, The Dutch Cancer Foundation, The Netherlands Organization for Scientific Research and the National Rheumatism Foundation. He conducted postdoctoral work at the University Hospital Utrecht and Ohio State University, before returning to Utrecht University in 1991. He is a part-time Professor of Immunotherapy at the University Medical Center. Dr. van de Winkel received a Ph.D. in Immunology, with his thesis on Human monocyte Fc receptors, in 1988 and a M.Sc. degree in Biology in 1985 from the University of Nijmegen, The Netherlands.

CEO Compensation
  • Jan G.'s compensation has been consistent with company performance over the past year, both up more than 20%.
  • Jan G.'s remuneration is higher than average for companies of similar size in Denmark.
Management Team Tenure

Average tenure and age of the Genmab management team in years:

5.7
Average Tenure
57
Average Age
  • The average tenure for the Genmab management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Jan G. van de Winkel

TITLE
Co-Founder
COMPENSATION
DKK28M
AGE
57
TENURE
9 yrs

David Eatwell

TITLE
Executive VP & CFO
COMPENSATION
DKK16M
AGE
57
TENURE
11 yrs

Judith Klimovsky

TITLE
Executive VP & Chief Development Officer
COMPENSATION
DKK12M
AGE
60
TENURE
2.3 yrs

Peter Kristensen

TITLE
Associate Director of Legal & Non-Independent Director
COMPENSATION
DKK686K
AGE
43

Dan Bruno

TITLE
VP of Corporate Controller & Non-Independent Director
COMPENSATION
DKK686K
AGE
38

Jane Juel

TITLE
Senior Director of Operations & Resource Management

Peter Ros

TITLE
Senior Director of Finance & Accounting

Marisol Peron

TITLE
Head & Corporate VP
TENURE
0.3 yrs

Birgitte Stephensen

TITLE
Senior Vice President of IPR & Legal
AGE
57
TENURE
9.4 yrs

Anthony Pagano

TITLE
Senior Vice President of Global Finance & Corporate Development
AGE
40
TENURE
0.3 yrs
Board of Directors Tenure

Average tenure and age of the Genmab board of directors in years:

3.4
Average Tenure
57
Average Age
  • The tenure for the Genmab board of directors is about average.
Board of Directors

Mats Pettersson

TITLE
Chairman
COMPENSATION
DKK2M
AGE
73

Deirdre Connelly

TITLE
Deputy Chairman
COMPENSATION
DKK2M
AGE
57
TENURE
1.2 yrs

Peter Kristensen

TITLE
Associate Director of Legal & Non-Independent Director
COMPENSATION
DKK686K
AGE
43
TENURE
3.4 yrs

Dan Bruno

TITLE
VP of Corporate Controller & Non-Independent Director
COMPENSATION
DKK686K
AGE
38
TENURE
3.4 yrs

Mijke Zachariasse

TITLE
Associate Director of Protein Production & Chemistry and Non-Independent Director
AGE
44
TENURE
0.3 yrs

Anders Pedersen

TITLE
Non-Independent Director
COMPENSATION
DKK1M
AGE
67
TENURE
15.6 yrs

Paolo Paoletti

TITLE
Independent Director
COMPENSATION
DKK1M
AGE
67
TENURE
4.4 yrs

Pernille Erenbjerg

TITLE
Independent Director
COMPENSATION
DKK1M
AGE
51
TENURE
4.4 yrs

Rolf Hoffmann

TITLE
Independent Director
COMPENSATION
DKK1M
AGE
59
TENURE
2.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (DKK) Value (DKK)
X
Management checks
We assess Genmab's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Genmab has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Genmab A/S (CPH:GEN): What We Can Expect From This Growth Stock

After Genmab A/S's (CPH:GEN) earnings announcement on 31 March 2019, analysts seem fairly confident, with earnings expected to grow by 44% in the upcoming year relative to the past 5-year average growth rate of 34%. … To understand the overall trajectory of GEN's earnings growth over these next fews years, I've fitted a line through these analyst earnings forecast to determine an annual growth rate from the slope. … CPSE:GEN Past and Future Earnings, May 23rd 2019 From the current net income level of ø1.5b and the final forecast of ø3.4b by 2022, the annual rate of growth for GEN’s earnings is 24%.

Simply Wall St -

How Much Of Genmab A/S (CPH:GEN) Do Institutions Own?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … Companies that used to be publicly owned tend to have lower insider ownership. … Companies of this size are usually well known to retail investors, too.

Simply Wall St -

Despite Its High P/E Ratio, Is Genmab A/S (CPH:GEN) Still Undervalued?

This article is for investors who would like to improve their understanding of price to earnings ratios (P/E ratios). … How Do I Calculate Genmab's Price To Earnings Ratio … Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Simply Wall St -

Why Genmab A/S (CPH:GEN) Is A Financially Healthy Company

Investors looking for stocks with high market liquidity and zero debt on the balance sheet should consider Genmab A/S (CPH:GEN). … With a market valuation of ø69b, GEN is a safe haven in times of market uncertainty due to its strong balance sheet. … In times of low liquidity in the market, these firms won’t be left high and dry.

Simply Wall St -

Should You Worry About Genmab A/S's (CPH:GEN) CEO Pay?

First, this article will compare CEO compensation with compensation at other large companies. … van de Winkel's Compensation Compare With Similar Sized Companies. … According to our data, Genmab A/S has a market capitalization of ø72b, and pays its CEO total annual compensation worth ø27m.

Simply Wall St -

Is Genmab A/S's (CPH:GEN) Stock Available For A Good Price After Accounting For Growth?

Genmab A/S (CPH:GEN) is a stock well-positioned for future growth, but many investors are wondering whether its last closing price of DKK1183 is based on unrealistic expectations. … How is GEN going to perform in the future. … One reason why investors are attracted to GEN is the high growth potential in the near future

Simply Wall St -

With A Return On Equity Of 18%, Has Genmab A/S's (CPH:GEN) Management Done Well?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … One way to conceptualize this, is that for each DKK1 of shareholders' equity it has, the company made DKK0.18 in profit. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Investors Who Bought Genmab (CPH:GEN) Shares Five Years Ago Are Now Up 367%

And highest quality companies can see their share prices grow by huge amounts. … During five years of share price growth, Genmab achieved compound earnings per share (EPS) growth of 77% per year. … The EPS growth is more impressive than the yearly share price gain of 36% over the same period.

Simply Wall St -

Genmab A/S (CPH:GEN) Has Attractive Fundamentals

As an investor, I look for investments which does not compromise one fundamental factor for another. … By this I mean, I look at stocks holistically, from their financial health to their future outlook. … is a company with great financial health as well as a.

Simply Wall St -

It's Time To Buy Genmab A/S (CPH:GEN)

Help shape the future of investing tools and receive a $20 prize! … The risk of investing in the stock market is a systematic crash. … But this risk is also an opportunity for those that understand the fickle nature of the market.

Simply Wall St -

Company Info

Description

Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL). Its products under development include Ofatumumab to treat CLL and multiple sclerosis; Daratumumab to treat MM, natural killer/T-cell lymphoma, and amyloidosis; Tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-AXL-ADC, and HexaBody-DR5/DR5 for treating solid cancers; and DuoBody-CD3xCD20 for the treatment of B-cell malignancies. The company’s products under development also comprise Teprotumumab for the treatment of Graves' orbitopathy; Camidanlumab tesirine (ADCT-301) to treat lymphoma, solid tumors, and acute myeloid leukemia (AML); HuMax-IL8 (BMS-986253) for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 to treat AML; JNJ-64007957 and JNJ-64407564 for MM; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs, including naked, bispecific, and immune effector function enhanced antibodies. The company has commercial license and collaboration agreement with Seattle Genetics, Inc. to co-develop tisotumab vedotin, an antibody-drug conjugate; and research collaboration and license agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.

Details
Name: Genmab A/S
GEN
Exchange: CPSE
Founded: 1999
DKK72,721,387,314
61,680,566
Website: http://www.genmab.com
Address: Genmab A/S
Kalvebod Brygge 43,
Copenhagen,
Capital Region of Denmark, 1560,
Denmark
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
CPSE GEN Ordinary Shares OMX Nordic Exchange Copenhagen DK DKK 18. Oct 2000
OTCPK GNMS.F Ordinary Shares Pink Sheets LLC US USD 18. Oct 2000
DB GE9 Ordinary Shares Deutsche Boerse AG DE EUR 18. Oct 2000
LSE 0MGB Ordinary Shares London Stock Exchange GB DKK 18. Oct 2000
BATS-CHIXE GENC Ordinary Shares BATS 'Chi-X Europe' GB DKK 18. Oct 2000
OTCPK GMXA.Y SPONSORED ADR Pink Sheets LLC US USD 31. May 2013
Number of employees
Current staff
Staff numbers
419
Genmab employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/16 20:43
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/10
Last earnings filing: 2019/05/08
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.